#Stem Cell Therapy macular degeneration Cost in India

[medacess]

✨ Can stem cell therapy cure macular degeneration in India? ✨

Wondering if stem cell therapy could be the answer to macular degeneration in India? 🌏👁️ This groundbreaking approach aims to restore vision potential and give new light to those with sight challenges.

[stemcellcure11-blog]

With the emergence of stem cell treatment in India, now, the treatment of macular degeneration is really a possibility. best cure for macular degeneration through stem cell treatment, one has to take the help of the Stem Cell Cure.

[beststemcellcure]

What Is Macular Degeneration and How to Cure It?

Macular degeneration is one of the prominent eye diseases, especially common in old age people. All the readers of this article, if you are recently diagnosed with macular degeneration, or you suspect macular degeneration in your dear ones then read this whole article carefully. This article will help you with a better understanding of the macular degeneration. For further information about the macular degeneration treatment and the precaution measure, you can even contact our experts.

Macular Degeneration

Macular degeneration, also known as age-related macular degeneration (AMD) is an eye disease in which the macula an integral central part of the retina gets damaged. It results in the loss of vision and the capability of eyes to differentiate between the objects. It affects the central and not the side vision of eye, which means if you are diseased with macular degeneration you can see the clock and the numbers clearly but you won’t be able to see the hands.

Types of AMD

There are two types of macular degeneration Wet and Dry. Around 85-90% of macular degeneration case is of dry type and the rest 10-15% are of wet type.

Dry AMD

In Dry AMD, the parts of the macula in the retina portion get thinner with the age and tiny clumps of protein grow around the area called drusen grow. It leads to the gradual loss of the vision. At present, there is no permanent solution for Dry AMD but it can be controlled and slowed down with dietary supplements containing foods rich in vitamins, lutein and zeaxanthin. The diet supplements and sunglasses are a more feasible way to protect your eye from further deterioration.

Wet AMD

Wet AMD is less common, but it is more dangerous than Dry AMD because in this condition you lose your vision more quickly than in Dry AMD. In Wet AMD abnormal blood vessels develop around the retina area, which sometimes leaks fluids and blood, causing scarring of the macula. Due to its quick reaction, many people fail to recognize it at an early stage and realize when it causes blurred vision. Hence, it is advised to have a regular visit to an opthalmologist, who can easily detect the signs and symptoms of Wet AMD in its early stage.

Who are at Risk of Macular Regeneration?

Ageing is a primary risk of macular degeneration. After the age of 40 years, the chances of AMD increase after each decade. One person should visit the eye specialist regularly to avoid any serious damage. The other risk factors are

Eating high saturated fat in your diet like meat, butter and cheese.

Overweight and smoking habit

Hypertension and genetic history of AMD.

High blood pressure and old age.

These are some of the risk factors that stimulate the chances of macular degeneration. It’s better to take preventive measure to keep yourself safe in advance.

Symptoms and causes of Macular Degeneration

Both Dry and Wet macular degeneration show different kinds of symptoms. Usually, Wet macular degeneration shows a sudden and quick response to our eyes which includes-

Visual distortions

Loss of central vision in one or both of the eyes.

Decreased intensify

Blind-spot in your field of vision.

Haziness in your vision

On the other hand, the symptoms of Dry macular degeneration are: –

Reduced Central vision and Visual distortions

Need brighter light for reading and doing minute work.

Increased blurriness in viewing objects.

Decreased intensify

Many researches have been taken place but there is no concrete information about what exactly causes macular degeneration. Some research indicates that it is caused by some hereditary and environmental factors whereas other claims it as a resultant effect of diet and smoking. This disease gets more complicated when the person progressed to central vision loss, which leads to a higher risk of social isolation and depression due to visual hallucinations.

Macular Degeneration treatment

At present doctors use drugs and surgical treatment to cure Wet macular degeneration, but it has more chances of getting the things worse. Because surgical treatment has more side-effects than benefits, and it may worsen the Dry AMD underlying below the Wet AMD.

Treat your Macular Degeneration from our Stem Cell Therapy

The ongoing stem cell research is helping scientists to understand the functioning of cells in the retina, which helps them to diagnose macular degeneration more effectively. At present, Stem Cell Therapy is the only hope for treating macular degeneration and other kinds of eye disorders like retinopathy, optic nerve damage and retinitis pigmentosa.

Stem Cell Treatment has shown proven results in treating AMD and recovering some percentage of vision back. The advance research is going on in improving the effectiveness of Stem Cell Treatment in India. Stem Cell Therapy is a safe and effective way to cure macular degeneration without causing any side effects on the patient. The stem cell treatment provides three important advantages in treating macular degeneration disease which are-

Stem Cell helps in regeneration of macular cells.

It also stops further deterioration of macular cells.

Overall, it helps in improving the vision of the diseased person.

Stem Cell Transplant for Macular Degeneration

We at Stem Cell Cure provides you with an effective treatment for macular degeneration. As per our treatment procedure, we cure our patients with mesenchymal stem cell injection through the retrobulbar and intra-vitreous route, which we decide after clinical assessment. This contributes to the regeneration process of macular cells and also helps in improving the vision of the patient. It also stops further deterioration of macular cells.  

Stem cell therapy is a regenerative medicinal practice which uses stem cells to cure serious diseases. We at stem cell cure provides you with a complete side-effect free treatment with satisfactory results. We have cured thousands of patients across India with more than 80% success rate. We strive to offer you the best quality service in terms of professional doctors, advance technology medical solutions and a clean & safe environment.

For more information please contact our experts on +91-9891818024 (24*7 helpline). You can also visit our website https://www.stemcellcure.in to book your appointment. Get cost-effective stem cell treatment in India from Stem Cell Cure, a clinic devoted to stem cell therapy located in New Delhi.

Stem Cell Treatment in Europe , Stem Cell Treatment in Europe , Stem Cell Treatment in Canada , Stem Cell Treatment in USA , Optic Nerve Atrophy Treatment , Spinal Cord Injury Treatment , Muscular Dystrophy Treatment 

[marketresearchinsightsrepor-blog]

Tissue Engineering Market is expected to reach USD 11.53 billion by 2022

Global tissue engineering market is expected to reach USD 11.53 billion by 2022, according to a new report by Grand View Research, Inc. The demand for tissue engineering is expected to upsurge owing to the shift of focus from stem cell therapies to immunocelluar therapies. Moreover, companies such as Caladrius and Celyad changed their names from Cardio3 Bio NeoStem respectively to reflect their focus on immunotherapies. 

The market is also experiencing industry-academia collaboration to make the commercialization of viable cell therapies possible. In July 2015, Fate Therapeutics, Inc. collaborated with theUniversity of Minnesota to research on Natural Killer (NK) therapeutics, which can detectand kill the malignant cells. The research is expected to accelerate with the use of programmed therapeutics by Fate Therapeutics. 

With the technological advancements, researchers are working upon custom-made body parts with the aid of biomaterials and bio 3D printing. The demand for orthopedic implants is continuously growing; however, there is a gap between the demand and supply. To address such issues, researchers are experimenting with ways to find out alternatives, which use in-vitro testing and humane substitutes. 

Investigators are working on ways to develop 3D printed organs, which can offer low-cost implantation. This step can revolutionize the 3D printing industry, but many hurdles such as donor availability, technologically-advanced 3D printers, and financial barriers have to be overcome. For instance, the cost of 3D printing ranges from USD 100 for tracheal split to USD 40,000 for nose bio-printing. Thus, there is a need for scientists and researchers to work on this multidisciplinary aspect of bio-printing.

To request a sample copy or view summary of this report, click the link below: http://www.grandviewresearch.com/industry-analysis/tissue-engineering-and-regeneration-industry

Further key findings from the study suggest:

Orthopedics dominated the application segment in 2014 owing to the continuous launch of new products and research funding. In February 2016, Geistlich Pharma launched a range of bone harvesting instrument for the efficient collection of autogenous bone. Implant of only autogenous bone causes resorption and volume depletion. With the use of Geistlich Bio-Oss-pioneered technology, the volume as well as properties of bone is restored. 

North America was the largest regional market with a revenue share estimated at over 50% owing to the various mergers and acquisitions along with huge funds available for research. In March 2016, Zimmer Bimet acquired Ortho Transmission for its pioneered technology, which could restore limb amputee patients. 

By acquiring the skeletal implant technology, Zimmer can efficiently work on its current project received by the U.S. Department of Defense to develop external prosthetic limbs. Moreover, in February 2016, Canadian scientists from the University of Toronto’s dentistry pioneered a 3D printed method for absorbable bone-implant. 

Europe was the second largest market in 2014, due to the amount of research and the funding received by the research universities. For instance, in June 2014, the European Union funded the VascuBone project to offer an alternative to bone grafts. The University Hospital of Wurzburg developed a toolbox to bring together the solutions required to offer ideal therapy to patients. 

Countries in Europe are also expanding their research knowledge by partnering with other countries’ research firms. For instance, in March 2013, Johannes Gutenberg University Mainz and Chinese Academy of Sciences formed the Chinese-German Joint Center for Bio-Inspired Materials. The scientists will work on using marine animals for osteoporosis medication. 

Asia Pacific is the fastest growing regional segment on the account of increasing interest of foreign players to establish their facilities in economically developed countries such as India and Japan. In August 2013, the Japan Health Ministry approved the clinical trial of the developing induced pluriponent stem (iPS) cells for blindness. The cells are morphed into retinal cells and then given to six patients with macular degeneration (AMD). 

India is in an ascent stage of research and trying to develop in the tissue engineering area. In February 2016, India Biotechnology Event was held, where experts blamed the snail pace of development to the tedious and long approval process. The suggestion was to adopt Japan’s new executed law, where the sponsor has to demonstrate only the safety and efficacy studies of the device. 

Key players of this market includeMedtronic, Inc., Zimmer Biomet, Acelity, Acell, Inc., Athersys, Inc., Organogenesis, Inc., Stryker Corporation, Tissue Regenix Group Plc, RTI surgical, Inc., and ReproCell, Inc. 

Industry contributors are establishing their market presence by acquiring other companies or by launching new products in the market. In November 2015, ReproCell, Inc. acquired Biopta to leverage on Bipota’s clinical network in the U.S and the UK. Biopta has worked on around 500 new medicines and has partnerships with Scottish Enterprise and the NHS. Moreover, in February 2016, RTI Surgical, Inc. received exclusive licensing rights by RTI Surgical, Inc. Through this, RTI can access the OPM’s OsteoFab technology for spinal procedures.

See More Reports of This Category: http://www.grandviewresearch.com/industry/biotechnology

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:

Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com Web: www.grandviewresearch.com

[grandviewresearchinc-blog]

Tissue Engineering Market is expected to reach USD 11.53 billion by 2022

Global tissue engineering market is expected to reach USD 11.53 billion by 2022, according to a new report by Grand View Research, Inc. The demand for tissue engineering is expected to upsurge owing to the shift of focus from stem cell therapies to immunocelluar therapies. Moreover, companies such as Caladrius and Celyad changed their names from Cardio3 Bio NeoStem respectively to reflect their focus on immunotherapies.

The market is also experiencing industry-academia collaboration to make the commercialization of viable cell therapies possible. In July 2015, Fate Therapeutics, Inc. collaborated with theUniversity of Minnesota to research on Natural Killer (NK) therapeutics, which can detectand kill the malignant cells. The research is expected to accelerate with the use of programmed therapeutics by Fate Therapeutics.

With the technological advancements, researchers are working upon custom-made body parts with the aid of biomaterials and bio 3D printing. The demand for orthopedic implants is continuously growing; however, there is a gap between the demand and supply. To address such issues, researchers are experimenting with ways to find out alternatives, which use in-vitro testing and humane substitutes.

Investigators are working on ways to develop 3D printed organs, which can offer low-cost implantation. This step can revolutionize the 3D printing industry, but many hurdles such as donor availability, technologically-advanced 3D printers, and financial barriers have to be overcome. For instance, the cost of 3D printing ranges from USD 100 for tracheal split to USD 40,000 for nose bio-printing. Thus, there is a need for scientists and researchers to work on this multidisciplinary aspect of bio-printing.

To request a sample copy or view summary of this report, click the link below: http://www.grandviewresearch.com/industry-analysis/tissue-engineering-and-regeneration-industry

Further key findings from the study suggest:

Orthopedics dominated the application segment in 2014 owing to the continuous launch of new products and research funding. In February 2016, Geistlich Pharma launched a range of bone harvesting instrument for the efficient collection of autogenous bone. Implant of only autogenous bone causes resorption and volume depletion. With the use of Geistlich Bio-Oss-pioneered technology, the volume as well as properties of bone is restored.

North America was the largest regional market with a revenue share estimated at over 50% owing to the various mergers and acquisitions along with huge funds available for research. In March 2016, Zimmer Bimet acquired Ortho Transmission for its pioneered technology, which could restore limb amputee patients.

By acquiring the skeletal implant technology, Zimmer can efficiently work on its current project received by the U.S. Department of Defense to develop external prosthetic limbs. Moreover, in February 2016, Canadian scientists from the University of Toronto’s dentistry pioneered a 3D printed method for absorbable bone-implant.

Europe was the second largest market in 2014, due to the amount of research and the funding received by the research universities. For instance, in June 2014, the European Union funded the VascuBone project to offer an alternative to bone grafts. The University Hospital of Wurzburg developed a toolbox to bring together the solutions required to offer ideal therapy to patients.

Countries in Europe are also expanding their research knowledge by partnering with other countries’ research firms. For instance, in March 2013, Johannes Gutenberg University Mainz and Chinese Academy of Sciences formed the Chinese-German Joint Center for Bio-Inspired Materials. The scientists will work on using marine animals for osteoporosis medication.

Asia Pacific is the fastest growing regional segment on the account of increasing interest of foreign players to establish their facilities in economically developed countries such as India and Japan. In August 2013, the Japan Health Ministry approved the clinical trial of the developing induced pluriponent stem (iPS) cells for blindness. The cells are morphed into retinal cells and then given to six patients with macular degeneration (AMD).

India is in an ascent stage of research and trying to develop in the tissue engineering area. In February 2016, India Biotechnology Event was held, where experts blamed the snail pace of development to the tedious and long approval process. The suggestion was to adopt Japan’s new executed law, where the sponsor has to demonstrate only the safety and efficacy studies of the device.

Key players of this market includeMedtronic, Inc., Zimmer Biomet, Acelity, Acell, Inc., Athersys, Inc., Organogenesis, Inc., Stryker Corporation, Tissue Regenix Group Plc, RTI surgical, Inc., and ReproCell, Inc.

Industry contributors are establishing their market presence by acquiring other companies or by launching new products in the market. In November 2015, ReproCell, Inc. acquired Biopta to leverage on Bipota’s clinical network in the U.S and the UK. Biopta has worked on around 500 new medicines and has partnerships with Scottish Enterprise and the NHS. Moreover, in February 2016, RTI Surgical, Inc. received exclusive licensing rights by RTI Surgical, Inc. Through this, RTI can access the OPM’s OsteoFab technology for spinal procedures.

See More Reports of This Category: http://www.grandviewresearch.com/industry/biotechnology

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:

Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com Web: www.grandviewresearch.com

[medacess]

Which Stem Cell is Beneficial for Treating Macular Degeneration?

Discover the power of stem cell therapy in combating macular degeneration! Umbilical cord-derived cells and bone marrow derived cells show promising results in restoring vision and slowing the progression of this condition. 🌿